Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate bolsters trade programs

This article was originally published in The Tan Sheet

Executive Summary

The Colgate toothpaste marketer is increasing its emphasis on trade spending with "sharper" programs to win consumers at the shelf, while also working to strengthen its partnership programs with retailers, Colgate-Palmolive President and CEO Ian Cook says. Programs to engage the consumer could provide an edge over competitors, as between 50 percent to 70 percent of final purchase decisions are made in-store, the executive noted during the Barclays Capital Back-To-School Consumer Conference Sept. 7. "These in-store activities relate to trial for new products as we are doing with our Colgate Sensitive Pro-Relief," Cook said. In Poland, the company employs in-store representatives to explain the benefits of Pro-Relief. The firm announced in 2009 it would create an "emotional connection" with financially strapped consumers via shelf programs offering a clear value proposition (1"The Tan Sheet" Feb. 2, 2009)

You may also be interested in...



Colgate Jumps On Weak Ad Market To Reconnect With Consumers

Colgate-Palmolive is capitalizing on the slumping ad market, purchasing media at a lower cost and launching campaigns to strengthen its emotional connection with consumers, the firm reported during an analyst meeting Jan. 29

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Changes To EU Pharma Reform: More Questions Than Answers?

In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel